skip to main content

The Science to Prevail

We are developing disease-modifying gene
therapies for patients with frontotemporal
dementia and other neurodegenerative disorders.


Prevail Therapeutics is developing PR006 as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN.

You are now leaving

You've clicked on a link for a third-party site, which Prevail Therapeutics does not control, influence, or endorse. Prevail is not responsible for any content on this third-party site, including the privacy policy. Click "Continue" to leave or "Go Back" to return to